Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.71 |
| ▸ | MAPK8 | P45983 | 18/20 | 0.71 |
| ▸ | MAPK9 | P45984 | 18/20 | 0.71 |
| ▸ | MAPK10 | P53779 | 18/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 16/20 | 0.71 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12979402 | 0.89 | MAPK1 (0.58) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL12979153 | 0.88 | PIK3CA (0.76) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL12979443 | 0.87 | PIK3CA (0.64) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL12979147 | 0.87 | MAPK1 (0.66) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL5456225 | 0.86 | PIK3CA (0.73) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL12979131 | 0.86 | MAPK1 (0.54) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL5446207 | 0.85 | PIK3CA (0.71) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL12979097 | 0.85 | PIK3CA (0.71) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL12979478 | 0.84 | PIK3CA (0.61) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL12979641 | 0.83 | MAPK1 (0.51) | PIK3CAMAPK8MAPK9MAPK10MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694068-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | Æterna Zentaris GmbH (DE) | 2014-02-12 | — | — | EP | claimed |
| CN-103501788-A | Pyridopyrazine derivatives and their use | AETERNA ZENTARIS GMBH | 2014-01-08 | — | — | CN | claimed |
| US-20120259151-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | AETERNA ZENTARIS GMBH (DE) | 2012-10-11 | — | — | US | claimed |
| WO-2012136694-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | ÆTERNA ZENTARIS GMBH (DE) | 2012-10-11 | — | — | WO | claimed |
| US-8912189-B2 | Pyridopyrazine derivatives and their use | AETERNA ZENTARIS GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8912189-B2 | Pyridopyrazine derivatives and their use | AETERNA ZENTARIS GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8912189-B2 | Pyridopyrazine derivatives and their use | AETERNA ZENTARIS GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| EP-2694068-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | Æterna Zentaris GmbH (DE) | 2014-02-12 | — | — | EP | disclosed |
| CN-103501788-A | Pyridopyrazine derivatives and their use | AETERNA ZENTARIS GMBH | 2014-01-08 | — | — | CN | disclosed |
| US-20120259151-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | AETERNA ZENTARIS GMBH (DE) | 2012-10-11 | — | — | US | disclosed |
| US-20120259151-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | AETERNA ZENTARIS GMBH (DE) | 2012-10-11 | — | — | US | disclosed |
| WO-2012136694-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | ÆTERNA ZENTARIS GMBH (DE) | 2012-10-11 | — | — | WO | disclosed |
| WO-2012136694-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | ÆTERNA ZENTARIS GMBH (DE) | 2012-10-11 | — | — | WO | disclosed |
| US-20120259151-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | AETERNA ZENTARIS GMBH (DE) | 2012-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120259151-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | PLPBP, PDXK, MAP4K2 | PIK3CA 866/4885MAPK8 116/4885MAPK9 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.